Cargando…

The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels

BACKGROUND: Previous studies have reported high plasma concentrations of both intestinal apolipoprotein (apo) B-48-containing lipoproteins and PCSK9 in subjects with familial hypercholesterolemia (FH). However, the extent to which LDL receptor deficiency and PCSK9 levels influence plasma apoB-48 con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drouin-Chartier, Jean-Philippe, Hogue, Jean-Charles, Tremblay, André J., Bergeron, Jean, Lamarche, Benoît, Couture, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472856/ https://www.ncbi.nlm.nih.gov/pubmed/28619117 http://dx.doi.org/10.1186/s12944-017-0502-x

Ejemplares similares

Potential role of ATM in hepatocyte endocytosis of ApoE-deficient, ApoB48-containing lipoprotein in ApoE-deficient mice
por: WU, JIANHUA, et al.
Publicado: (2014)

Investigation of human apoB48 metabolism using a new, integrated non‐steady‐state model of apoB48 and apoB100 kinetics
por: Björnson, E., et al.
Publicado: (2019)

SAA is Found on ApoB-Containing Lipoproteins in Obese Diabetic Humans
por: Jahangiri, Anisa, et al.
Publicado: (2013)

n-3 Polyunsaturated Fatty Acid Supplementation Has No Effect on Postprandial Triglyceride-Rich Lipoprotein Kinetics in Men with Type 2 Diabetes
por: Tremblay, André J., et al.
Publicado: (2016)

ApoB48-Lipoproteins Are Associated with Cardiometabolic Risk in Adolescents with and without Polycystic Ovary Syndrome
por: Vine, Donna F, et al.
Publicado: (2020)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

ApoB48 as an Efficient Regulator of Intestinal Lipid Transport
por: Lo, Chunmin C., et al.
Publicado: (2020)

Chylomicrons produced by Caco‐2 cells contained ApoB‐48 with diameter of 80–200 nm
por: Nauli, Andromeda M., et al.
Publicado: (2014)

Regulation of plasma LDL: the apoB paradigm
por: Sniderman, Allan D., et al.
Publicado: (2009)

Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome
por: Meyers, Charles Daniel, et al.
Publicado: (2015)

Proteoglycan binding as proatherogenic function metric of apoB-containing lipoproteins and chronic kidney graft failure
por: Steffen, Hannah L.M., et al.
Publicado: (2021)

Impact of dairy consumption on essential hypertension: a clinical study
por: Drouin-Chartier, Jean-Philippe, et al.
Publicado: (2014)

Genetic Polymorphisms in LDLR, APOB, PCSK9 and Other Lipid Related Genes Associated with Familial Hypercholesterolemia in Malaysia
por: Lye, Say-Hean, et al.
Publicado: (2013)

Correlates of Coronary Artery Calcification Prevalence and Severity in Patients With Heterozygous Familial Hypercholesterolemia
por: Drouin-Chartier, Jean-Philippe, et al.
Publicado: (2020)

Impact of Diet on Plasma Lipids in Individuals with Heterozygous Familial Hypercholesterolemia: A Systematic Review of Randomized Controlled Nutritional Studies
por: Roy, Gabrielle, et al.
Publicado: (2021)

Biosynthesis of lipoprotein: location of nascent apoAI and apoB in the rough endoplasmic reticulum of chicken hepatocytes
Publicado: (1992)

Susceptibility of ApoB and PCSK9 Genetic Polymorphisms to Diabetic Kidney Disease Among Chinese Diabetic Patients
por: Ma, Liang, et al.
Publicado: (2021)

Subjects with Molecularly Defined Familial Hypercholesterolemia or Familial Defective apoB-100 Are Not Being Adequately Treated
por: Leren, Trond P., et al.
Publicado: (2011)

Racial differences between African-American and white women in insulin resistance and visceral adiposity are associated with differences in apoCIII containing apoAI and apoB lipoproteins
por: Wang, Liyun, et al.
Publicado: (2014)

Hepatic S1P deficiency lowers plasma cholesterol levels in apoB-containing lipoproteins when LDLR function is compromised
por: Basu, Debapriya, et al.
Publicado: (2015)

ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator
por: Kido, Toshimi, et al.
Publicado: (2017)

Elevated ApoB/apoA-1 is Associated with in-Hospital Mortality in Elderly Patients with Acute Myocardial Infarction
por: Chen, Yan, et al.
Publicado: (2023)

Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels
por: Lee, Chan Joo, et al.
Publicado: (2017)

ApoB/ApoA‐I Ratio is Associated With Faster Hemodynamic Progression of Aortic Stenosis: Results From the PROGRESSA (Metabolic Determinants of the Progression of Aortic Stenosis) Study
por: Tastet, Lionel, et al.
Publicado: (2018)

Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes
por: Labonté, Marie-Ève, et al.
Publicado: (2013)

Mouse, but Not Human, ApoB-100 Lipoprotein Cholesterol Is a Potent Innate Inhibitor of Streptococcus pneumoniae Pneumolysin
por: Wade, Kristin R., et al.
Publicado: (2014)

Comparison of Apolipoprotein (apoB/apoA-I) and Lipoprotein (Total Cholesterol/HDL) Ratio Determinants. Focus on Obesity, Diet and Alcohol Intake
por: Tognon, Gianluca, et al.
Publicado: (2012)

ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report
por: Reeskamp, Laurens F., et al.
Publicado: (2021)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
por: Matta, Anthony, et al.
Publicado: (2021)

Evidence for Beneficial Associations between Isoenergetic Macronutrient Exchanges and Serum non-HDL Cholesterol, a Measure of All Circulating Atherogenic, apoB-Containing Lipoproteins
por: Griffin, Bruce A, et al.
Publicado: (2021)

Associations between insulin-like growth factor binding protein-2 and lipoprotein kinetics in men
por: Rauzier, Chloé, et al.
Publicado: (2022)

Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study
por: Walldius, Göran, et al.
Publicado: (2021)

A Comparison of Lipids and apoB in Asian Indians and Americans
por: Singh, Kavita, et al.
Publicado: (2021)

Elevated ApoB/ApoA-I ratio is associated with acute anti-N-Methyl-D-aspartate receptor encephalitis, but not disease outcomes
por: Liu, Yingying, et al.
Publicado: (2022)

Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE(-/-) mice
por: Dunér, Pontus, et al.
Publicado: (2021)

Plasma biomarkers of small intestine adaptations in obesity-related metabolic alterations
por: Lalande, Catherine, et al.
Publicado: (2020)

Increased Circulating Levels of PCSK9 and Pro-Atherogenic Lipoprotein Profile in Pregnant Women with Maternal Supraphysiological Hypercholesterolemia
por: Cantin, Claudette, et al.
Publicado: (2022)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

Elevated Lipoprotein(a) Level Influences Familial Hypercholesterolemia Diagnosis
por: Chubykina, Uliana V., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sr9rlh8aivg99vj045aim49jnf